Market Access, Computer Science, People

The ability to concisely communicate the value provided by a health technology is integral to its success.  At AIX Consultancy, we pride ourselves in our ability to convey the value of our clients’ technologies to key stakeholders using a step-wise structured framework:

• Evaluate: We make a concerted effort to comprehend the technology and take into account a wide range of variables, such as epidemiology, disease burden, treatment hurdles, unmet needs, clinical value, health economic value, competitive advantages, and cost.  In doing this we are able to identify gaps as well as areas of best fit
• Design: Based on the gaps and/or areas of best fit identified, we develop a value preposition and story that is scientifically robust, visually impactful and easy to comprehend
• Validate: With the assistance of stakeholders in our extensive global payer/KOL network, we test the value preposition and collect feedback
• Refine: The value preposition is refined to ensure optimal value demonstration

Health technology pricing and reimbursement, particular for software, is evolving to keep up with the demands of a dynamic market.  Determining the optimal pricing and revenue model can be challenging due to differing regulatory and comparative evidence requirements across markets.  Our knowledge of market access and computer science offers our clients the best chance at maximising the value of their health technology, whether it be a new drug, medical device, or healthcare AI tool

Many health technologies are partnered or licensed to aid development and long-term success.  We are able to carry out pricing and commercial due diligence efficiently utilising our 4-corner framework (competitors, analogues, cost-utility/budget impact thresholds, and external payer/KOL input) to help inform strategic decision making

Numerous countries around the world rely on health economic analysis to inform reimbursement decisions.  At AIX Consultancy, we can develop tools efficiently to help estimate and demonstrate the value for money of a health technology, as well as its financial impact on the healthcare setting.  This includes cost-effectiveness and budget-impact models  using a variety of structures (Markov, decision-tree, discrete-event simulation) across a variety of platforms (Excel/VBA, R, Python, native apps).  Our models are:

• Accurate: Created using the most up-to-date evidence available, with the option for external validation of inputs and structure by payers/KOLs
• Bespoke: Tailored to meet clients’ requirements and desired platform of use
• Impactful: Visually impactful outputs to aid decision-making
  

Some countries utilise International Reference Pricing (IRP) to determine prices of healthcare technologies.  This means that launch sequencing based on achievable prices is extremely important to maximise overall revenue.  At AIX Consultancy, we have developed our own IRP tool that allows clients to input bespoke scenarios to determine the optimal launch order based on expected price erosion

In light of the increasing regulatory acceptance of Real-World Evidence (RWE) and the growing demand for it from payers and physicians, we are able to efficiently generate and leverage real-world data.  Our experience includes studies using internal observational and registry data, as well as external data sources such as Clinical Practice Research Datalink (CPRD), Hospital Episode Statistics (HES), The Health Improvement Network (THIN), Optum, IBM/Truven and Flatiron.  As a result, we can query existing databases to provide insights into: 

• Potential target populations of interest by looking at real-world uptake, incidence or prevalence figures (epidemiological modelling), healthcare resource use, comorbidities and survival
• Outcomes and effectiveness of treatments
• Long-term safety vs effectiveness
• Possible evidence gaps based on competitor insights or external stakeholder (payer/KOL) feedback